ArticleClinical and translational science2022
Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.
Article in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recommendations to promote equity, diversity and inclusion in decentralized clinical trials.Nature medicine · 2024Guideline
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Advanced Proteomic Profiling Demonstrates Clinical Utility of Patient-Centric, at-Home Dried Blood Sample Collection.Journal of proteome research · 2026Article
- From Home to Transcriptome: Comparing the Transcriptomic Profile of Induced Immune Response via Lipopolysaccharide Stimulation in homeRNA and Venous Blood.Analytical chemistry · 2026Article
- Measurement of Centanafadine Concentrations in a Pharmacokinetic Trial: Comparison of Traditional Venipuncture Versus Blood Microsampling.Clinical and translational science · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- Advancing Early Clinical Trials: The Transformative Potential of Decentralized Designs and Digital Technologies in Phase 1 Clinical Trial.Clinical pharmacology and therapeutics · 2025Article
- Comparing capillary blood collection technologies: assessing patient experience, device performance, & clinical accuracy.Bioanalysis · 2025Article
- Comparing Participant Experiences of at-Home and Hospital-Based Biological Sampling: Cross-Sectional Insights From the SIREN Study.Health science reports · 2025Article
- From Home to Transcriptome: Comparing the transcriptomic profile of induced immune response via lipopolysaccharide stimulation in homeRNA and venous blood.bioRxiv : the preprint server for biology · 2025Article
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion.Clinical and translational science · 2025Review
- A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient-Centric Microsampling.Clinical and translational science · 2025Article
- Quantitation of BCAA and BCKA in plasma and patient-centric dried blood microsamples in a clinical setting.Bioanalysis · 2025Article
- Integrating metering capabilities to increase the utility of self-collected, dried samples.Bioanalysis · 2025Article
- Microsampling techniques and patient-centric therapeutic drug monitoring of immunosuppressants.Bioanalysis · 2025Review
- Clinical evaluation of patterned dried plasma spot cards to support quantification of HIV viral load and reflexive genotyping.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals.Contemporary clinical trials communications · 2025Article
- Your Blood is Out for Delivery: Considerations of Shipping Time and Temperature on Degradation of RNA from Stabilized Whole Blood.Analytical chemistry · 2025Article
- Capillary Blood Self-Sampling for Therapeutic Drug Monitoring: A Mixed-Methods Usability Study of the True DoseBioMed research international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in the technologies to enable patient-centric sampling (PCS) have the potential to improve blood sample collection by enabling clinical trial participants to collect samples via self-collection or with the help of a caregiver in their home. Typically, blood samples to assess pharmacokinetics and pharmacodynamics of a drug during clinical development are collected at a clinical site via venous blood draw. In this position paper by the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), the potential value PCS can bring to patients, to the clinical datasets generated, and to clinical trial sponsors is discussed, along with considerations for program decision making, bioanalytical feasibility, operations, and regulatory implications. With an understanding of the value of PCS and considerations when implementing during clinical drug development, we can bring the promise of PCS closer to reality and enable decentralized clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.